GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma

BMC Pulmonary Medicine

Table 3 Correlation of GPC3 expression with the clinical phenotypes of lung adenocarcinoma (LUAD) samples

Characteristics	Variable	Number of patients	GPC3 expression				Test	P value
Characteristics	Variable	Number of patients	High	Percent (%)	Low	Percent (%)	Test	P value
Age	≥ 65	310	146	55.9	164	53.8	Wilcoxon	0.1332
	< 65	256	115	44.1	141	46.2
Location	Central Lung	67	29	39.2	38	30.9	Wilcoxon	0.2896
	Peripheral Lung	130	45	60.8	85	69.1
years_smoked	≥ 41	160	105	62.5	129	57.1	Wilcoxon	0.5824
	< 41	234	63	37.5	97	42.9
pathologic_M	M0	394	1	0.4	1	0.3	Kruskal	0.7793
	M1	20	3	1.1	2	0.6
	M1a	2	6	2.3	14	4.4
	M1b	5	176	66.7	218	69.2
	MX	158	78	29.5	80	25.4
pathologic_N	N0	371	14	5.2	3	1	Kruskal	0.0141
	N1	107	177	65.8	194	61.6
	N2	87	38	14.1	69	21.9
	N3	2	39	14.5	48	15.2
	NX	17	1	0.4	1	0.3
pathologic_T	T1	82	24	8.9	25	7.9	Kruskal	0.0002
	T1a	49	34	12.6	26	8.3
	T1b	60	34	12.6	55	17.5
	T2	203	4	1.5	16	5.1
	T2a	89	14	5.2	15	4.8
	T2b	29	91	33.7	112	35.6
	T3	50	16	5.9	34	10.8
	T4	20	51	18.9	31	9.8
	TX	3	2	0.7	1	0.3
Radiation therapy	Yes	69	33	13.9	36	13.9	Wilcoxon	0.4830
	No	428	205	86.1	223	86.1
Gender	Female	316	110	40.7	159	50.5	Wilcoxon	0.0027
	Male	269	160	59.3	156	49.5
Tumor stage	I	316	163	61.5	153	49.2	Kruskal	0.0435
	II	135	11	4.2	17	5.5
	III	97	50	18.9	85	27.3
	IV	28	41	15.5	56	18

ISSN: 1471-2466